Clinical trial NCT01391013: A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients
Official title: A Randomised, Controlled, Open-Label Trial to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg O.D. Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Subjects With Undetectable Plasma HIV-1 RNA on Their Current Treatments.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Human Immunodeficiency Virus 1
Keywords: Human immunodeficiency virus 1
Acquired immunodeficiency syndrome
Immunologic deficiency syndrome
Darunavir/ritonavir
Darunavir
Ritonavir
Nucleoside reverse transcriptase inhibitors (NRTIs)
Prezista
Lead sponsor: Janssen-Cilag S.p.A.
Sponsor class: INDUSTRY
First posted: 2011-07-11
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare change of brachial artery flow mediated vasodilatation using Darunavir/Ritonavir (DRV/r) 800/100 mg once daily as a monotherapy (use of a single medication) versus a triple combination therapy containing 2 nucleoside reverse transcriptase inhibitors (NRTIs) and DRV/r in Human immunodeficiency virus-1 (HIV-1) infected participants.

Detailed description: This is a Phase II, randomized (the study medication is assigned by chance), open-label (all people know the identity of the intervention), controlled, single centre study. The study consists of 3 phases including, the screening phase (4 weeks before administration of study medication), treatment phase (48 weeks), and the follow-up phase (4 weeks). In the treatment phase, HIV-infected participants who have not changed their first-line treatment of highly active antiretroviral therapy (HAART) for at least 8 weeks and have documented evidence of their HIV- ribonucleic acid (RNA) measurements being virologically suppressed (HIV-RNA less than 50 copies/mL) for at least 24 weeks prior to the screening, will be randomly assigned equally in two treatment arms: triple combination therapy arm (DRV/r 800/100 mg once daily plus 2 NRTIs) or monotherapy arm (DRV/r 800/100 mg once daily). Participants in the triple combination arm who are already on 2 NRTIs prior to randomization may remain on these or switch them at baseline, where the participants on the monotherapy arm will discontinue HAART at baseline and will start DRV/r 800/100 mg once daily. Safety evaluations will include assessment of adverse events, significant vital signs, and significant laboratory tests. The total duration of the study will be 56 weeks.

Eligibility criteria: Inclusion Criteria: - Human immunodeficiency virus-1 (HIV-1) infected participants on their first-line treatment with highly active antiretroviral therapy (HAART) (combination of 2 or 3 nucleoside reverse transcriptase inhibitors \[NRTIs\] with at least 1 additional antiretroviral \[ARV\] from the non-nucleoside reverse transcriptase inhibitor \[NNRTI\] and/or protease inhibitors \[PI\] class) for at least 24 weeks, provided the same ARV combination for at least 8 weeks before screening

* Participants' preference for a more convenient regimen and/or any current or history of toxicity on actual regimen
* Plasma HIV-1 ribonucleic acid (RNA) less than 50 cp/ml for at least 24 weeks before screening, where single viral blips of more than 50 copies/mL are allowed
* Cluster of differentiation 4 (CD4) count more than 100/mm3 at the start of HAART and more than 200/mm3 at screening
* Healthy on the basis of physical examination, medical history, vital signs, clinical laboratory tests, and 12-lead electrocardiogram performed at screening
* Agrees to protocol-defined use of effective contraception
* Postmenopausal, surgically sterile, or abstinent female participants

Exclusion Criteria:

* History of coronary heart disease, uncontrolled hypertension, peripheral vascular disease and or cerebrovascular disease
* History of virological failure on highly active antiretroviral therapy, plasma HIV-1 ribonucleic acid more than 500 copies/mL after initial full virological suppression while on ARV therapy and any PI mutations
* Participants with significantly hepatic and liver insufficiency or diagnosed with acute viral hepatitis or have active clinically significant diseases and acquired immune deficiency syndrome (AIDS) defining illness at screening
* Current significant tobacco use, active drug or alcohol use or dependence
* Use of lipid-lowering drugs within 4 weeks prior to study entry and use of testosterone, anabolic steroids, oral contraceptives or hormonal replacement within 12 weeks prior to study entry or previous or current use of darunavir
* Use of systemic glucocorticoids, long-acting inhaled steroids (inhaled via mouth or nose), or other immunomodulators within 30 days prior to study entry

Primary outcomes:
measure: Change From Baseline to Week 24 in Brachial Artery Flow Mediated Vasodilatation (FMD): Median Change in FMD (%)
timeFrame: Baseline (Day 1 of Week 1) to Week 24
Secondary outcomes:
measure: Change From Baseline to Week 48 in Brachial Artery FMD: Median Change in FMD (%)
timeFrame: Baseline to Week 48
measure: Number of Participants With a Human Immunodeficiency Virus- Ribonucleic Acid (HIV-RNA) Greater Than or Equal to 50 Copies/mL
timeFrame: Screening (Week -4), Week 1 (Day 1), Week 4, Week 12, Week 24, Week 36, Week 48, and follow-up (Week 52)
measure: Change From Baseline to Week 48 in Circulating Endothelial Cells
timeFrame: Baseline to Week 48
measure: Change From Baseline to Week 48 in Precursors of Circulating Endothelial Cells
timeFrame: Baseline to Week 48
measure: Change From Baseline in Mean Low-density Lipoprotein (LDL) Cholesterol at Week 24 and Week 48: Median Change in LDL
timeFrame: Baseline (Day1 of Week 1), Week 24, and Week 48
measure: Change From Baseline in Mean High-density Lipoprotein (HDL) Cholesterol at Week 24 and Week 48: Median Change in HDL
timeFrame: Baseline, Week 24, and Week 48
measure: Change From Baseline in Mean Triglycerides at Week 24 and Week 48: Median Change in Triglycerides
timeFrame: Baseline, Week 24, and Week 48
measure: Change From Baseline in Insulin Sensitivity at Week 24 and Week 48: Median Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
timeFrame: Baseline, Week 24, and Week 48
measure: Change From Baseline in Mean Framingham Risk Score at Week 24 and Week 48: Medican Change in Framingham Risk Score
timeFrame: Baseline, Week 24, and Week 48
measure: Change From Baseline to Week 48 in Leg Fat Content: Median Change in Leg Fat (Total)
timeFrame: Baseline to Week 48
measure: Change From Baseline to Week 48 in Visceral Fat Content in Abdomen: Median Change in Visceral Abdominal Tissue (VAT)
timeFrame: Baseline to Week 48
measure: Change From Baseline to Week 48 in Femoral Neck T Score: Median Change in Femoral Neck T Score
timeFrame: Baseline to Week 48
measure: Change From Baseline to Week 48 in Femoral Neck Z Score: Median Change in Femoral Neck Z Score
timeFrame: Baseline to Week 48
measure: Change From Baseline to Week 48 in Lumbar T Score: Median Change in Lumbar T Score
timeFrame: Baseline to Week 48
measure: Change From Baseline to Week 48 in Lumbar Z Score: Median Change in Lumbar Z Score
timeFrame: Baseline to Week 48
measure: Change From Baseline in Cluster of Differentiation 4 (CD4) Count Over Week 48
timeFrame: Screening (Week -4), Week 1 (Day 1), Week 4, Week 12, Week 24, Week 36, Week 48, and follow-up (Week 52)
Other outcomes:
Locations:
Study officials:
affiliation: Janssen-Cilag S.p.A.
name: Janssen-Cilag S.p.A. Clinical Trial
role: STUDY_DIRECTOR
References: